NASDAQ:LBPH Longboard Pharmaceuticals (LBPH) Stock Price, News & Analysis $37.40 +1.58 (+4.41%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$35.69▼$38.1150-Day Range$17.55▼$39.5052-Week Range$3.60▼$40.48Volume588,182 shsAverage Volume943,937 shsMarket Capitalization$1.45 billionP/E RatioN/ADividend YieldN/APrice Target$54.63 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Longboard Pharmaceuticals alerts: Email Address Longboard Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside46.1% Upside$54.63 Price TargetShort InterestBearish13.60% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.91Based on 8 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.82) to ($2.43) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.81 out of 5 starsMedical Sector448th out of 936 stocksPharmaceutical Preparations Industry206th out of 436 stocks 4.5 Analyst's Opinion Consensus RatingLongboard Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageLongboard Pharmaceuticals has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Longboard Pharmaceuticals' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted13.60% of the float of Longboard Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverLongboard Pharmaceuticals has a short interest ratio ("days to cover") of 8.7.Change versus previous monthShort interest in Longboard Pharmaceuticals has recently increased by 3.95%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldLongboard Pharmaceuticals does not currently pay a dividend.Dividend GrowthLongboard Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LBPH. Previous Next 3.8 News and Social Media Coverage News SentimentLongboard Pharmaceuticals has a news sentiment score of 0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Longboard Pharmaceuticals this week, compared to 3 articles on an average week.Search Interest13 people have searched for LBPH on MarketBeat in the last 30 days. MarketBeat Follows7 people have added Longboard Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Longboard Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.64% of the stock of Longboard Pharmaceuticals is held by insiders.Percentage Held by Institutions63.28% of the stock of Longboard Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Longboard Pharmaceuticals' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Longboard Pharmaceuticals are expected to decrease in the coming year, from ($1.82) to ($2.43) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Longboard Pharmaceuticals is -16.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Longboard Pharmaceuticals is -16.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLongboard Pharmaceuticals has a P/B Ratio of 22.40. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Longboard Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Longboard Pharmaceuticals Stock (NASDAQ:LBPH)Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel and transformative medicines for neurological diseases. The company develops bexicaserin (LP352), which has completed Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. It also develops LP659, an S1P receptor modulator for the treatment of neurological diseases. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.Read More LBPH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LBPH Stock News HeadlinesJuly 23, 2024 | fool.com3 Russell 2000 Growth Stocks That Could Be Worth the RiskJuly 20, 2024 | americanbankingnews.comLongboard Pharmaceuticals, Inc. (NASDAQ:LBPH) Given Consensus Recommendation of "Buy" by AnalystsJuly 27, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.July 17, 2024 | americanbankingnews.comLongboard Pharmaceuticals (NASDAQ:LBPH) Shares Up 5.2%July 3, 2024 | businesswire.comLongboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)July 3, 2024 | benzinga.comTop 3 Health Care Stocks That May Crash This QuarterJuly 1, 2024 | businesswire.comLongboard Pharmaceuticals Receives Breakthrough Therapy Designation for Bexicaserin (LP352)May 14, 2024 | morningstar.comLongboard Pharmaceuticals Inc LBPHJuly 27, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.May 7, 2024 | markets.businessinsider.comBuy Rating Affirmed for Longboard Pharmaceuticals Amidst Positive Clinical Progress and Market Potential for BexicaserinMay 6, 2024 | businesswire.comLongboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)May 4, 2024 | finance.yahoo.comLongboard Pharmaceuticals Inc. (LBPH) Q1 2024 Earnings: Financial and Strategic DevelopmentsMay 3, 2024 | msn.comLongboard Pharmaceuticals EPS of -$0.42 beats by $0.07May 2, 2024 | markets.businessinsider.comBuy Rating Affirmed on Longboard Pharmaceuticals with Promising Bexicaserin Developments and Regulatory Milestones AheadMay 2, 2024 | investorplace.comLBPH Stock Earnings: Longboard Pharmaceuticals Beats EPS for Q1 2024May 2, 2024 | businesswire.comLongboard Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate UpdatesMay 2, 2024 | msn.comBaird Initiates Coverage of Longboard Pharmaceuticals (LBPH) with Outperform RecommendationApril 17, 2024 | markets.businessinsider.comBexicaserin’s Promising Future: Buy Rating Justified by Strong Clinical Data and Potential Blockbuster StatusSee More Headlines Receive LBPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Longboard Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/02/2024Today7/27/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:LBPH CUSIPN/A CIK1832168 Webwww.longboardpharma.com Phone619-592-9775FaxN/AEmployees50Year FoundedN/APrice Target and Rating Average Stock Price Target$54.63 High Stock Price Target$90.00 Low Stock Price Target$32.00 Potential Upside/Downside+46.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($2.24) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-54,420,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-49.87% Return on Assets-46.04% Debt Debt-to-Equity RatioN/A Current Ratio31.43 Quick Ratio31.43 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.67 per share Price / Book22.40Miscellaneous Outstanding Shares38,880,000Free Float37,076,000Market Cap$1.45 billion OptionableOptionable Beta1.24 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Kevin R. Lind (Age 48)President, CEO, Secretary & Director Comp: $1.07MMs. Brandi L. Roberts CPA (Age 50)M.B.A., Executive VP & CFO Comp: $662.65kDr. Randall E. Kaye M.D. (Age 62)Executive VP & Chief Medical Officer Comp: $717.95kMr. Chadwick J. Orevillo MPHExecutive VP & Head of OperationsMegan E. KnightVP & Head of Investor RelationsMr. Steven W. Spector J.D. (Age 59)Executive VP, Head of Business Development & General Counsel Dr. Anne M. Danks Ph.D.VP & Head of Nonclinical Research & DevelopmentMr. Gus CardenasVP & Head of Quality AssuranceDr. Marco Peters Ph.D.VP & Head of Translational ScienceDr. Dewey McLin Ph.D.VP & Head of Medical AffairsMore ExecutivesKey CompetitorsSocietal CDMONASDAQ:SCTLBridgeBio PharmaNASDAQ:BBIOApellis PharmaceuticalsNASDAQ:APLSAvidity BiosciencesNASDAQ:RNACrinetics PharmaceuticalsNASDAQ:CRNXView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 23,774 shares on 7/26/2024Ownership: 0.238%Farallon Capital Management LLCBought 1,380,000 shares on 5/24/2024Ownership: 7.563%RA Capital Management L.P.Bought 3,289,119 shares on 5/17/2024Ownership: 8.460%AWM Investment Company Inc.Bought 211,518 shares on 5/16/2024Ownership: 0.544%California State Teachers Retirement SystemBought 19,183 shares on 5/16/2024Ownership: 0.056%View All Insider TransactionsView All Institutional Transactions LBPH Stock Analysis - Frequently Asked Questions How have LBPH shares performed this year? Longboard Pharmaceuticals' stock was trading at $6.03 at the beginning of the year. Since then, LBPH stock has increased by 520.2% and is now trading at $37.40. View the best growth stocks for 2024 here. How were Longboard Pharmaceuticals' earnings last quarter? Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH) announced its quarterly earnings data on Thursday, May, 2nd. The company reported ($0.42) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.48) by $0.06. When did Longboard Pharmaceuticals IPO? Longboard Pharmaceuticals (LBPH) raised $75 million in an IPO on Friday, March 12th 2021. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Citigroup, Evercore ISI, Guggenheim Securities and Cantor served as the underwriters for the IPO. Who are Longboard Pharmaceuticals' major shareholders? Top institutional shareholders of Longboard Pharmaceuticals include Bank of New York Mellon Corp (0.24%). View institutional ownership trends. How do I buy shares of Longboard Pharmaceuticals? Shares of LBPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:LBPH) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredThe #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredDon't Pay a Dime for Marc Lichtenfeld's Top AI PicksUsually, you'd have to plunk down a hefty sum to get your hands on Marc Lichtenfeld's latest income research.....The Oxford Club | SponsoredThe asset beating inflation by 4xCentral Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire invest...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Longboard Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Longboard Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
